Multiple crossmatch-incompatible red blood cell transfusions in a patient with anti-Yta (Cartwright) antibodies without hemolytic transfusion reactions: case report

Read full text Summarise with VIRAT
Authors: Jazmine Ramos, William Nicholas Rose
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Anti-Yta is a relatively rare antibody directed against the high-prevalence Yta antigen in the Cartwright blood group system. Anti-Yta exhibits variable clinical significance, with documented reports of both hemolytic transfusion reactions (HTRs) and lack of clinical hemolysis following transfusion of Yt(a+) red blood cells (RBCs). The monocyte monolayer assay (MMA) has been shown to help predict the potential of an antibody to result in an HTR, but published clinical correlations are limited. This report describes a patient with anti-Yta who tolerated multiple Yt(a+) RBC transfusions without an evident HTR, consistent with his negative MMA results. Case Description: A 72-year-old male underwent open surgical repair of a ruptured type IV thoracoabdominal aneurysm with subsequent need for RBC transfusions. Antibody screening on post-operative day (POD) 17 revealed anti-Yta after the patient already received 31 RBC transfusions. Given the variable clinical significance of anti-Yta, an initial MMA was performed to help predict the safety of Yt(a+) RBC transfusions. A repeat MMA was performed to ensure that subsequent Yt(a+) RBC transfusions remained safe. Despite indirect antiglobulin testing (performed as part of the MMA evaluation) demonstrating strong (up to 3.5+) immunoglobulin G (IgG) reactivity with Yt(a+) RBCs, both MMA results showed less than five percent reactivity, indicating low risk for HTR with antigen-positive crossmatch-incompatible blood. After negative MMA testing, the patient received four crossmatch-incompatible RBC units over three separate occasions without clinical or laboratory evidence of hemolysis, including stable post-transfusion hemoglobin and haptoglobin. The patient was discharged on POD 49, with no documentation of subsequent HTRs or additional RBC transfusions over the following 4 years. Conclusions: This case contributes a well-documented instance of a patient with anti-Yta tolerating serial crossmatch-incompatible RBC transfusions, consistent with negative MMA results. This highlights an example of the utility of using the MMA to help guide transfusion decision-making in patients with anti-Yta.

Fields of Study & Subjects

Blood groups and transfusion Blood transfusion and management Hemoglobinopathies and Related Disorders

Publication details

Journal / source
Annals of Blood
Volume
11
Pages
4–4
Publication date
1 March 2026
Language
EN